Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Deep Dive: Upper Digestive Cancers - Hepatocellular Carcinoma: from Molecule to Medicine

ESMO-Deep-Dive-Upper-Digestive-Cancers-1000x250-Hepatocellular-Cancer
Live on
07 Sep 2022 at 18:30 CEST

It is with great pleasure that we invite you to participate in the ESMO Deep Dive Webinar in hepatocellular carcinoma (HCC), elaborating the facts from understanding the molecular pathway to drug development and application.

This webinar is developed with the aim to inform on state-of-the-art strategies for treatment of patients with intermediate-stage HCC, to provide insights on optimal options for first-line systemic and locoregional treatment, and to highlight ongoing research in second line and beyond systemic treatment for HCC.

We will begin with a lecture on the changing paradigm of treating patients with intermediate-stage HCC. This will follow with elaboration of first-line treatment options. Finally, we will provide insights in second line and beyond systemic treatment for patients with HCC. The lectures will be followed by a live discussion with the full speakers’ panel.

The programme is designed to provide an overview of rapid progress in incorporating molecular targeting therapies and immune checkpoint inhibitors in the management of patients with HCC, offer expert opinion exchange and provide some important considerations. We strongly encourage and invite you to register and join us all in this new ESMO activity.

Prof. Ann-Lii Cheng
National Taiwan University, Taipei, Taiwan

AND

Prof. Arndt Vogel
Hannover Medical School (MHH), Hannover, Germany

Speakers

Programme

Time

Title

Speaker

5 min

Welcome and Introduction

Ann-Lii Cheng, Arndt Vogel

20 min

The changing paradigm of treating intermediate-stage HCC

Masatoshi Kudo

15 min

State of the art and future directions for application of radiotherapeutic approaches in HCC

Laura Dawson

20 min

First-line treatment options

Tim Meyer

20 min

Insight on the second line and beyond systemic therapy for HCC

Stephen Lam Chan

15 min

LIVE Q&A

All

A certificate of attendance and 2 ESMO-MORA category 1 points will be awarded for live attendance to this event

Learning objectives:

  • To inform on state-of-the-art strategies for treating intermediate-stage HCC patients
  • To provide insights on optimal first-line systemic and locoregional therapy options
  • To highlight ongoing research on second line and beyond systemic therapy for HCC

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.